Contrasting of ARCA biopharma Inc. (ABIO) and Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)

ARCA biopharma Inc. (NASDAQ:ABIO) and Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) are two firms in the Biotechnology that compete against each other. Below is a comparison of their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ARCA biopharma Inc. N/A 0.00 7.93M -0.82 0.00
Arrowhead Pharmaceuticals Inc. 47.29M 37.09 29.21M -0.35 0.00

Table 1 demonstrates ARCA biopharma Inc. and Arrowhead Pharmaceuticals Inc.’s top-line revenue, earnings per share and valuation.


Table 2 has ARCA biopharma Inc. and Arrowhead Pharmaceuticals Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
ARCA biopharma Inc. 0.00% 0% 0%
Arrowhead Pharmaceuticals Inc. -61.77% -24.1% -16.9%

Volatility & Risk

ARCA biopharma Inc. has a beta of 2.08 and its 108.00% more volatile than S&P 500. Arrowhead Pharmaceuticals Inc. has a 2.25 beta and it is 125.00% more volatile than S&P 500.


ARCA biopharma Inc.’s Current Ratio is 8.5 while its Quick Ratio is 8.5. On the competitive side is, Arrowhead Pharmaceuticals Inc. which has a 1.8 Current Ratio and a 1.8 Quick Ratio. ARCA biopharma Inc. is better positioned to pay off short and long-term obligations compared to Arrowhead Pharmaceuticals Inc.

Analyst Recommendations

The following table delivered below contains the ratings and recommendations for ARCA biopharma Inc. and Arrowhead Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
ARCA biopharma Inc. 0 0 0 0.00
Arrowhead Pharmaceuticals Inc. 0 0 1 3.00

Competitively Arrowhead Pharmaceuticals Inc. has an average target price of $165, with potential upside of 786.14%.

Institutional and Insider Ownership

ARCA biopharma Inc. and Arrowhead Pharmaceuticals Inc. has shares owned by institutional investors as follows: 15.4% and 63.7%. Insiders owned roughly 0.89% of ARCA biopharma Inc.’s shares. Competitively, insiders own roughly 4.4% of Arrowhead Pharmaceuticals Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ARCA biopharma Inc. 5.75% 9.55% -15.6% -24.74% -36.11% 37.93%
Arrowhead Pharmaceuticals Inc. 3.77% 40.51% 34.05% 35.15% 215.92% 59.74%

For the past year ARCA biopharma Inc. was less bullish than Arrowhead Pharmaceuticals Inc.

ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. The company's lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in chronic heart failure patients with reduced left ventricular ejection fraction. It also engages in the development of a preclinical plan for AB171, a new chemical entity for the treatment of various cardiovascular indications, such as peripheral arterial disease and chronic heart failure. The company has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. Its pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. The company also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreements with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.